## Journal for

# **İmmunoTherapy of Cancer**

Official Journal of the Society for Immunotherapy of Cancer







### Journal for

## ImmunoTherapy of Cancer

### 2021 RATES & DATA

The Journal for ImmunoTherapy of Cancer (JITC) is the leading open access journal in tumor immunology and cancer immunotherapy.

JITC aims to enrich communication and advance scientific understanding in this rapidly evolving field. Content includes high-quality original research articles and authoritative reviews written by recognized, leading scientists and clinicians.

**Primary readership**: Scientists, academicians, researchers, clinicians and government representatives who work in oncology and/or immunology.

JITC is the official journal of the Society for Immunotherapy of Cancer, representing more than 3,000 members from 31 medical specialties in 40 countries around the world.

Digital traffic		
Global visitors*		143k
Global page views*		247k
U.S. visitors*		62k
U.S. page views*		114k
e-Newsletter recipients		10k
Global eTOC recipients	Contact a sales representative for	2.2k+
* Source: Google Analytics, January - June 2020	the latest figures.	

At a glance	
Year established:	2013
Impact factor:	10.252*
Rank	16/244 in Oncology 10/158 in Immunology*
Editor-in-Chief:	Pedro Romero, MD
Online Frequency:	Continuously published

<sup>\*</sup> Source: 2019 Journal Citation Reports®, Clarivate Analytics, 2020




# ADVERTISING OPPORTUNITIES



Online advertising options available, as well as tailored packages including:

- Reprints and ePrints
- Email table of content (eTOC) alerts
  - 2,200+ recipients
  - Includes opted-in SITC members
- e-Newsletter advertising
  - Sponsor an authentic JITC content email
  - Sent to opted-in SITC members and U.S. medical oncologists and immunologists

JITC online offers the opportunity to target your products through geo-targeted, online advertising. There are a full range of digital opportunities available.



#### DIGITAL ADVERTISING RATES

	Pixels	Rate	Minimum charge	Specifications	
Website mobile banner	468 x 60	\$79 per 1,000 impressions	\$1,885 for 25,000 impressions	File type GIFs (animated preferred) and Rich Media accepted, subject to production	
Website leaderboard	728 x 90	\$79 per 1,000 impressions	\$3,765 for 50,000 impressions	clearance. File size up to 50k.  Deadline to receive materials 5 working days prior to deployment.	
Website MPU (Mid page unit)	300 x 250	\$84 per 1,000 impressions	\$2,030 for 25,000 impressions		
eTOC alert leaderboard	320 x 100	Please contact Jim Cunningham at jcunningham@cunnasso.com for the latest email advertising rates.		JPEG or GIF accepted  Please note: Advertisements are	
eTOC alert MPU	300 x 250	Please contact Jim Cunningham at jcunningham@cunnasso.com for the latest email advertising rates.		accepted subject to availability and BMJ approval.	
e-Newsletter	600 x 90	Please contact Jim Cunningham at jcunningham@cunnasso.com for the latest email advertising rates.			




# TARGETED SOLUTIONS

JITC 2021 Rates & Data

Hurry! Limited opportunities available.

#### E-NEWSLETTER SPONSORSHIP






## **TARGETED SOLUTIONS**



Hurry! Limited opportunities available.

#### DIGITAL ROADBLOCK PACKAGE



For more information on advertising, and to discuss your campaign requirements, please contact: JIM CUNNINGHAM National Accounts Manager (201) 767-4170 office (201) 394-4426 cell jcunningham@cunnasso.com

Open as a webpage » nical/translational cancer immunotherapy I Oncolytic and local nunotherapy I Basic tumor immunology I Immunotherapy narkers I Immune cell therapies and immune cell engineering I Clinical/translational cancer immunotherapy · Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA Pedro Barata, Neeraj Agarwal, Roberto Nussenzveig et al. (2020-08-11) · Oxazaphosphorines combined with immune checkpoint blockers: dose-Julia Delahousse, Charles Skarbek, Mélanie Desbois et al. (2020-08-11) 10.1136/jitc-2020-000916 · Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma M Hope Robinson, Juan Vasquez, Akhilesh Kaushal et al. (2020-08-11) 10.1136/iitc-2020-001066 Oncolytic and local immunotherapy · Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning Jonathan G Pol, Matthew J Atherton, Kyle B Stephenson et al. (2020-08-13) 10.1136/iitc-2020-000981 Your ad here

